Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Long-Term Deferred Tax (2024 - 2025)

Oric Pharmaceuticals filings provide 2 years of Long-Term Deferred Tax readings, the most recent being $2.1 million for Q4 2025.

  • Quarterly Long-Term Deferred Tax fell 18.36% to $2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2025, down 18.36% year-over-year, with the annual reading at $2.1 million for FY2025, 18.36% down from the prior year.
  • Long-Term Deferred Tax hit $2.1 million in Q4 2025 for Oric Pharmaceuticals, down from $2.6 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $2.6 million in Q4 2024 and bottomed at $2.1 million in Q4 2025.